Abstract
Aim: Since 2010 that the combination of platinum / pemetrexed is approved as first line therapy for advanced (locally advanced or metastatic) nonsquamous non-small cell lung cancer (NSCLC). Our aim is to assess the effectiveness of first-line pemetrexed plus platinum for advanced nonsquamous NSCLC in clinical practice.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
